Get the Stockscreener App
49.65
4.62%
2.24
Exact Sciences Corp stock is traded at $49.65, with a volume of 705.37K.
It is up +4.62% in the last 24 hours and down -10.21% over the past month.
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
See More
Previous Close:
$47.41
Open:
$47.36
24h Volume:
705.37K
Relative Volume:
0.33
Market Cap:
$8.78B
Revenue:
$2.69B
Net Income/Loss:
$-214.04M
P/E Ratio:
-42.44
EPS:
-1.17
Net Cash Flow:
$98.43M
1W Performance:
-3.28%
1M Performance:
-10.21%
6M Performance:
-17.35%
1Y Performance:
-16.56%
1-Day Range:
$47.22
$49.72
1-Week Range:
$46.55
$51.31
52-Week Range:
$40.62
$79.62
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
49.57 | 8.78B | 2.69B | -214.04M | 98.43M | -1.17 |
|
TMO
Thermo Fisher Scientific Inc
|
523.99 | 198.19B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
206.75 | 148.92B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
127.70 | 36.52B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
438.93 | 35.63B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
187.41 | 33.12B | 15.41B | 1.37B | 2.11B | 7.50 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
EXACT Sciences Corp. to Host Earnings Call - ACCESS Newswire
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by New York State Common Retirement Fund - MarketBeat
Heritage Investors Management Corp Has $4.29 Million Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Generali Investments Towarzystwo Funduszy Inwestycyjnych Acquires 6,000 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences (NASDAQ:EXAS) Price Target Cut to $70.00 by Analysts at Piper Sandler - MarketBeat
Exact Sciences (NASDAQ:EXAS) Shares Up 4.8% After Analyst Upgrade - MarketBeat
Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire Inc.
2 Stocks Down 59% and 34% to Buy and Hold - The Globe and Mail
Exact Sciences to Participate in March Investor Conferences - BioSpace
Exact Sciences price target raised to $73 from $70 at Scotiabank - TipRanks
Healthcare Spotlight: Exact Sciences Takes Center Stage at Two Major March Conferences - StockTitan
Exact Sciences (NASDAQ:EXAS) Price Target Lowered to $65.00 at Bank of America - MarketBeat
Exact Sciences Stock Climbs After Strong Q2 Results - MSN
symbol__ Stock Quote Price and Forecast - CNN
Exact Sciences Reports Strong Revenue Growth in 2024 - TipRanks
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday? - Benzinga
Exact Sciences Corp Earnings Call Highlights Growth - TipRanks
Exact Sciences Earnings: Guidance at the Low End of Our Expectations, but Shares Remain Attractive - Morningstar
Exact Sciences Has an Established Colon Cancer Screening Franchise and a Progressing Pipeline - Morningstar
Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts - Benzinga
TD Cowen sees upside in Exact Sciences stock, maintains $86 target - Investing.com
Exact Sciences stock price target cut to $65 at BTIG - Investing.com India
Exact Sciences Corporation (NASDAQ:EXAS) Q4 2024 Earnings Call Transcript - Insider Monkey
Exact Sciences stock price target cut to $65 at BTIG By Investing.com - Investing.com South Africa
EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y - Yahoo Finance
Exact Sciences Reports Robust Q4 Earnings, Surpassing Revenue ProjectionsNews and Statistics - IndexBox, Inc.
Exact Sciences (EXAS) PT Lowered to $65 at BTIG - StreetInsider.com
Exact Sciences: Q4 Earnings Snapshot - mySA
Exact Sciences Corp (EXAS) Q4 2024 Earnings Call Highlights: Str - GuruFocus.com
Exact Sciences Corp (EXAS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Exact Sciences 2025 revenue guidance range includes consensus - MSN
Exact Sciences Announces Fourth Quarter 2024 Results - BioSpace
Exact Sciences Corp reports results for the quarter ended December 31Earnings Summary - TradingView
EXACT SCIENCES Earnings Results: $EXAS Reports Quarterly Earnings - Nasdaq
Exact Sciences Corp Plans To Launch Three New Cancer Tests In 2025 -February 19, 2025 at 05:44 pm EST - Marketscreener.com
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
EXACT SCIENCES CORP SEC 10-K Report - TradingView
Exact Sciences Stock Slides On Q4 Earnings: The Details - Benzinga India
Exact Sciences stock falls despite Q4 earnings beat By Investing.com - Investing.com Australia
Exact Sciences stock falls despite Q4 earnings beat - Investing.com India
Exact Sciences: Q4 Earnings Snapshot -February 19, 2025 at 04:43 pm EST - Marketscreener.com
Exact Sciences Q4 Net Loss Widens, Revenue Up; Sets Outlook -February 19, 2025 at 04:22 pm EST - Marketscreener.com
EXACT Sciences earnings beat by $0.27, revenue topped estimates - Investing.com
Exact Sciences Corp. Reports Fourth Quarter and Full Year 2024 Results - TradingView
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy’s Petition Challenging Validity of a Second Patent Asserted by Exact Sciences - Business Wire
Banque Pictet & Cie SA Has $3.97 Million Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences (EXAS) Projected to Post Earnings on Wednesday - MarketBeat
8,508 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors - MarketBeat
Barclays sets Exact Sciences stock price target at $70 with Overweight rating - MSN
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exact Sciences Corp Stock (EXAS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Baranick Brian | EVP, GM, Precision Oncology |
Feb 25 '25 |
Option Exercise |
0.00 |
3,954 |
0 |
19,841 |
| Herriott James | SVP, General Counsel & Sec |
Feb 25 '25 |
Option Exercise |
0.00 |
1,647 |
0 |
13,738 |
| ORVILLE JACOB A | EVP, GM, Screening |
Feb 25 '25 |
Option Exercise |
0.00 |
3,954 |
0 |
22,136 |
| Conroy Kevin T | President and CEO |
Feb 25 '25 |
Option Exercise |
0.00 |
13,180 |
0 |
1,121,378 |
| Conroy Kevin T | President and CEO |
Feb 19 '25 |
Option Exercise |
0.00 |
10,374 |
0 |
1,084,565 |
| COWARD D SCOTT | Director |
Feb 19 '25 |
Option Exercise |
0.00 |
2,248 |
0 |
52,831 |
| ORVILLE JACOB A | EVP, GM, Screening |
Feb 19 '25 |
Option Exercise |
0.00 |
2,248 |
0 |
16,688 |
| Baranick Brian | EVP, GM, Precision Oncology |
Feb 19 '25 |
Option Exercise |
0.00 |
1,729 |
0 |
14,487 |
| Condella Sarah | EVP, Human Resources |
Feb 19 '25 |
Option Exercise |
0.00 |
2,248 |
0 |
74,859 |
| Herriott James | SVP, General Counsel & Sec |
Feb 19 '25 |
Option Exercise |
0.00 |
865 |
0 |
10,731 |
5.14%
2.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):